KR20240033017A - 알츠하이머병 치료를 위한 바이오마커 - Google Patents

알츠하이머병 치료를 위한 바이오마커 Download PDF

Info

Publication number
KR20240033017A
KR20240033017A KR1020247004758A KR20247004758A KR20240033017A KR 20240033017 A KR20240033017 A KR 20240033017A KR 1020247004758 A KR1020247004758 A KR 1020247004758A KR 20247004758 A KR20247004758 A KR 20247004758A KR 20240033017 A KR20240033017 A KR 20240033017A
Authority
KR
South Korea
Prior art keywords
subject
months
treatment
ratio
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247004758A
Other languages
English (en)
Korean (ko)
Inventor
채드 스완슨
아키히코 고야마
미치오 가네키요
마이클 이리재리
린 크레이머
준 캐플로
데이비드 버벨
쇼바 다다
팔라비 사츠데브
라리사 레이더만
세이이치 하야토
이샤니 랜드리
로버트 고든
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20240033017A publication Critical patent/KR20240033017A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020247004758A 2021-07-09 2022-07-08 알츠하이머병 치료를 위한 바이오마커 Pending KR20240033017A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163220434P 2021-07-09 2021-07-09
US63/220,434 2021-07-09
US202163203444P 2021-07-22 2021-07-22
US63/203,444 2021-07-22
US202163263255P 2021-10-29 2021-10-29
US63/263,255 2021-10-29
US202163263928P 2021-11-11 2021-11-11
US63/263,928 2021-11-11
US202163264551P 2021-11-24 2021-11-24
US63/264,551 2021-11-24
US202263306028P 2022-02-02 2022-02-02
US63/306,028 2022-02-02
US202263269372P 2022-03-15 2022-03-15
US63/269,372 2022-03-15
US202263364618P 2022-05-12 2022-05-12
US63/364,618 2022-05-12
PCT/US2022/073576 WO2023283650A1 (en) 2021-07-09 2022-07-08 Biomarkers for alzheimer's disease treatment

Publications (1)

Publication Number Publication Date
KR20240033017A true KR20240033017A (ko) 2024-03-12

Family

ID=83232761

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247004758A Pending KR20240033017A (ko) 2021-07-09 2022-07-08 알츠하이머병 치료를 위한 바이오마커

Country Status (11)

Country Link
US (1) US20250163135A1 (https=)
EP (1) EP4367516A1 (https=)
JP (1) JP2024525559A (https=)
KR (1) KR20240033017A (https=)
AU (1) AU2022307687A1 (https=)
CA (1) CA3225302A1 (https=)
CL (1) CL2024000063A1 (https=)
IL (1) IL309468A (https=)
MX (1) MX2023015183A (https=)
TW (1) TW202317192A (https=)
WO (1) WO2023283650A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118777453A (zh) * 2024-06-25 2024-10-15 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
WO2025019457A1 (en) * 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025260029A1 (en) 2024-06-14 2025-12-18 Eisai R&D Management Co., Ltd. Method for quantifying amyloid beta protofibril
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
RS67249B1 (sr) 2020-03-20 2025-10-31 Eisai R&D Man Co Ltd Formulacije antitela visoke koncentracije protiv protofibrila amiloid beta peptida i metode njihove upotrebe
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
TWI843040B (zh) * 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118777453A (zh) * 2024-06-25 2024-10-15 上海交通大学医学院附属瑞金医院 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法

Also Published As

Publication number Publication date
CA3225302A1 (en) 2023-01-12
JP2024525559A (ja) 2024-07-12
MX2023015183A (es) 2024-03-14
CL2024000063A1 (es) 2024-08-02
AU2022307687A1 (en) 2024-01-04
EP4367516A1 (en) 2024-05-15
US20250163135A1 (en) 2025-05-22
TW202317192A (zh) 2023-05-01
IL309468A (en) 2024-02-01
WO2023283650A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
Karran et al. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
US20250163135A1 (en) Biomarkers for alzheimer's disease treatment
Panza et al. Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?
Selkoe The advent of Alzheimer treatments will change the trajectory of human aging
Farlow Treatment of mild cognitive impairment (MCI)
US20250377367A1 (en) Methods of treatment using p-tau181 level
JP7676556B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータ抗体及びその使用
TW202019471A (zh) 阿茲海默症之治療及預防方法
EP3464350A1 (en) Methods for treating alzheimer's disease
KR20250114372A (ko) 타우(tau) pet 수준을 이용하는 치료 방법
Lozupone et al. Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead
KR20240053620A (ko) 항-a베타 프로토피브릴 항체의 피하 제형 및 이를 사용하는 방법
CN117940773A (zh) 用于阿尔茨海默病治疗的生物标记物
CN118786141A (zh) 使用p-tau181水平的治疗方法
WO2026015877A1 (en) Fluid biomarker
KR20260038283A (ko) 항미생물 펩티드
Flores Mapping Therapeutic Pathways From Neuropsychiatric Disorders to Alzheimer's Disease
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
CN118829445A (zh) 用于治疗阿尔茨海默病的方法
Krance The Longitudinal Relationships Between Biomarkers of Alzheimer’s Disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000